Psychogenomics

Numerous studies have shown that mental disorders arise from the interaction of personal experiences and genomic factors. Genomic factors also play a role in the improvement of mental disorders. For a more detailed understanding of the response to psychopharmacological drugs and to psychotherapy, the symptoms of the disorder are important, as well as possibly genomic variations and the levels of the psychopharmacological drugs. Therapeutic drug monitoring (TDM) may also be helpful in this regard. The research group is dedicated to better understanding the interaction of these different factors.

Contact

Management:
Prof. Dr. Rainald Mössner

+49 7071 29-82307

E-mail address: rainald.moessner@med.uni-tuebingen.de

Current projects

Significance of genetic factors for symptom improvement through psychotherapy

Hereditary factors play a role in the improvement of psychological symptoms. There is already evidence that this is true for the response to drug treatment. It may be possible in the future to select an optimal medication according to a patient's individual genomic characteristics. This is the aim of pharmacogenomics as part of research approaches to achieve advances in Personalised Medicine. The project will investigate whether the success of psychotherapeutic treatment is also influenced by hereditary factors. (Prof. Dr. Rainald Mössner)

Selected publications

Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mössner R, Müller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P.
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.
Pharmacopsychiatry. 2018 Jan;51(1-02):9-62.
Fabbri C, Hosak L, Mössner R, Giegling I, Mandelli L, Bellivier F, Claes S, Collier DA, Corrales A, Delisi LE, Gallo C, Gill M, Kennedy JL, Leboyer M, Lisoway A, Maier W, Marquez M, Massat I, Mors O, Muglia P, Nöthen MM, O'Donovan MC, Ospina-Duque J, Propping P, Shi Y, St Clair D, Thibaut F, Cichon S, Mendlewicz J, Rujescu D, Serretti A.
Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response.
World Journal of Biological Psychiatry. 2017 Feb;18(1):5-28.
Giegling I, Hosak L, Mössner R, Serretti A, Bellivier F, Claes S, Collier DA, Corrales A, Delisi LE, Gallo C, Gill M, Kennedy JL, Leboyer, M, Maier W, Marquez M, Massat I, Mors O, Muglia P, Nothen MM, Ospina-Duque J, Owen MJ, Propping P, Shi Y, St Clair D, Thibaut F, Cichon S, Mendlewicz J, O’Donovan MC, Rujescu D.
Genetics of Schizophrenia. A Consensus paper of the WFSBP Task Force on Genetics.
World Journal of Biological Psychiatry 2017 Oct;18(7):492-505.
Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, Skaug J, Shago M, Mössner R, Pinto D, Ren Y, Thiruvahindrapduram B, Fiebig A, Schreiber S, Friedman J, Ketelaars CE, Vos YJ, Ficicioglu C, Kirkpatrick S, Nicolson R, Sloman L, Summers A, Gibbons CA, Teebi A, Chitayat D, Weksberg R, Thompson A, Vardy C, Crosbie V, Luscombe S, Baatjes R, Zwaigenbaum L, Roberts W, Fernandez B, Szatmari P, Scherer SW.
Structural variation of chromosomes in autism spectrum disorder.
Am J Hum Genet 82: 477-88 (2008)
Mössner R, Marshall CR, Sutcliffe JS, Skaug J, Pinto D, Vincent J, Zwaigenbaum L, Fernandez B, Roberts W, Szatmari P, Scherer SW.
Contribution of SHANK3 mutations to autism spectrum disorder.
Am J Hum Genet 81: 1289-97 (2007)